👉 The Pal fluid, also known as palivizumab or Synagis, is a synthetic respiratory syncytial virus (RSV) fusion inhibitor used primarily to prevent severe RSV infections in high-risk infants, particularly those with chronic lung disease or congenital heart defects. It works by binding to the RSV fusion protein on the surface of the virus, thereby blocking its ability to fuse with and enter host cells. This prevents the virus from infecting respiratory epithelial cells, thus reducing the risk of severe RSV disease, such as bronchiolitis and pneumonia. Palivizumab is administered via intranasal spray and is typically given before the peak RSV season, usually in late fall to early winter, to provide optimal protection during this period.
